Comments on the poll question "Funding FDA Inspections"
Article
Your comments to the poll question: The proposed Food and Drug Administration Globalization Act of 2008 recommends imposing a fee for inspections to fund the cost of FDA inspections (both domestic and foreign inspections). If such a measure is adopted, how should the fee be assessed?
Your comments
"Regarding inspection fees, one approach for establishing fees would be to assess the actual cost or the average cost for doing the inspections after let’s say 100 inspections at various size manufacturing plants. The FDA could then establish, based on the size of the manufacturing facility, a fixed fee. The larger manufacturing facilities might have a larger fee. Many local governments set their fees based upon a historical average of what it costs to perform the task. The goal is that the local municipality is able to recover their out-of-pocket costs and not make any profit from the fees."
The question
The proposed Food and Drug Administration Globalization Act of 2008 recommends imposing a fee for inspections to fund the cost of FDA inspections (both domestic and foreign inspections). If such a measure is adopted, how should the fee be assessed?
1. On a facility basis, based on the size of the manufacturing facility. 2. On a company basis, based on company revenues. 3. On a company basis, based on the number of manufacturing facilities operated by the company. 4. A flat fee for all companies with pharmaceutical manufacturing facilities.
Click here to submit a comment. Go to the poll archive to see past questions and results.
Comments on the poll question "Funding FDA Inspections"
Your comments to the poll question: The proposed Food and Drug Administration Globalization Act of 2008 recommends imposing a fee for inspections to fund the cost of FDA inspections (both domestic and foreign inspections). If such a measure is adopted, how should the fee be assessed?
Your comments
The question
The proposed Food and Drug Administration Globalization Act of 2008 recommends imposing a fee for inspections to fund the cost of FDA inspections (both domestic and foreign inspections). If such a measure is adopted, how should the fee be assessed?
1. On a facility basis, based on the size of the manufacturing facility.
2. On a company basis, based on company revenues.
3. On a company basis, based on the number of manufacturing facilities operated by the company.
4. A flat fee for all companies with pharmaceutical manufacturing facilities.
Click here to submit a comment. Go to the poll archive to see past questions and results.
Merck KGaA Becomes Strategic Partner in Peregrine Ventures’ Incentive Incubator
Merck will have early-stage opportunities to help startups set up for future success in the pharmaceutical and life sciences fields.
Transformations in Drug Development for Cell and Gene Therapies
As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Trump Issues Executive Order Aimed at Reducing Prescription Drug Prices for US Patients
According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities domestically.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Improve Your Efficiency in Production
Example of how we offer creative and interesting solutions to our customers to improve efficiency in production.
Be Proactive Not Reactive
We want to inform our customers that we have an excellent tech center available to assist them to develop together tailor-made solutions and personalized technologies, solve problems and complete hands-on training on our machines.
Merck KGaA Becomes Strategic Partner in Peregrine Ventures’ Incentive Incubator
Merck will have early-stage opportunities to help startups set up for future success in the pharmaceutical and life sciences fields.
Transformations in Drug Development for Cell and Gene Therapies
As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Trump Issues Executive Order Aimed at Reducing Prescription Drug Prices for US Patients
According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities domestically.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Improve Your Efficiency in Production
Example of how we offer creative and interesting solutions to our customers to improve efficiency in production.
Be Proactive Not Reactive
We want to inform our customers that we have an excellent tech center available to assist them to develop together tailor-made solutions and personalized technologies, solve problems and complete hands-on training on our machines.